Martin David Harp

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Priya Vakharia, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

Maria H. Berrocal spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Eye symptoms such as dry, itchy, red, painful, watery, and gritty eyes can happen before the smoke is even noticeable.

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

Prevent Blindness has declared the month of August Children’s Eye Health and Safety Month. The goal of this initiative is to educate parents and caregivers on ways to keep children’s eyes healthy.

DAYLIGHT is the first of the company's 3 studies and was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high-intensity dosing regimen of tarcocimab tedromer.

Cognition Therapeutics has dosed the first participant in the phase 2 MAGNIFY study of CT1812. This oral therapy is being studied as a for geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

Akari remains on track and plans to submit an IND application to the US FDA in the first half of 2024, and plans on starting clinical trials in the second half of 2024

Vantage Surgical Solutions has acquired Ophthalmic Surgical Solutions (OSS). OSS is a Kansas-based company specializing in ophthalmic surgical equipment and services.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

Investigators have enrolled the 112 patients in the KALAHARI phase 2, part B clinical trial for diabetic macular edema (DME). This is above the originally planned total of 108 patients.

Caroline Baumal, MD shares an update on visual function data from DERBY and OAKS Studies based on her presentation at the 2023 Clinical Trials at the Summit annual meeting, held in Park City, Utah.

RAFARM and BioNanoSim have entered into an agreement to create a new Opthalmic company: BNS Opthalmics (BNSO).

World No Tobacco Day helps to bring focus onto risk factors and symptoms of early vision loss linked to smoking.

Prevent Blindness has declared the week of May 15-21 as Inherited Retinal Disease (IRD) Genetic Testing Week to promote awareness and provide resources to understand the impact of genetic testing and treatment options.

Roger Goldberg, MD, MBA, spoke with Ophthalmology Times® to share insights about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept.

Michael Ip, MD, highlighted the results of the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.

Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.

Christine Kay, MD, discussed research for the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting held in New Orleans.

Caroline Baumal, MD, spoke with our onsite team at the 2023 ARVO annual meeting to share more about Apellis' presentations focusing on visual function, imaging and artificial intelligence.

Dierck Hillmann, PhD, was interviewed by our onsite team at the 2023 ARVO annual meeting where he shared research on holographic optical coherence tomography (OCT).

Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.

Kaushal Solanki, PhD, CEO and founder of Eyenuk, shared news about the company's EyeArt AI, which is cleared by the FDA to detect diabetic retinopathy.